Literature DB >> 6885870

When is arthrography indicated in Legg-Calvé-Perthes disease?

J M Gallagher, D S Weiner, A J Cook.   

Abstract

We evaluated plain radiographs and arthrograms of twenty-one children with active Legg-Calvé-Perthes disease in order to determine the value of the arthrography. We found that when epiphyseal protrusion was shown by the arthrograms it could be seen on the plain radiographs as well in all patients. Also, an acetabulum-head index of less than 90 or an acetabulum-head quotient of less than 92 as determined on plain radiographs correlated well with a diagnosis of protrusion. Thus, an arthrogram is not necessary to make the diagnosis of protrusion in most patients. The arthrogram is more useful in delineating changes in the articular surface for prognoses concerning arthritis and in tailoring the treatment to the individual patient.

Entities:  

Mesh:

Year:  1983        PMID: 6885870

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  4 in total

Review 1.  Perthes' disease.

Authors:  P J Klisić
Journal:  Int Orthop       Date:  1984       Impact factor: 3.075

2.  Assessing the role of hip arthrography in the treatment decision making for children with Legg-Calvé-Perthes disease.

Authors:  Serkan Erkuş; Önder Kalenderer; Ali Turgut; Tayfun Bacaksız; Özkan Köse; Kıvanç Yüksel
Journal:  Acta Orthop Traumatol Turc       Date:  2020-09       Impact factor: 1.511

3.  Arthrographic indicators for decision making about femoral varus osteotomy in Legg-Calvé-Perthes disease.

Authors:  Makoto Kamegaya; Takashi Saisu; Makoto Takazawa; Junichi Nakamura
Journal:  J Child Orthop       Date:  2008-07-26       Impact factor: 1.548

4.  The Effect of Clinical Knowledge and Surgical Experience on Treatment Choice in Legg-Calve-Perthes Disease: Intra-observer and Inter-observer Reliability Study.

Authors:  Serkan Erkus; Onder Kalenderer; Ali Turgut; Tayfun Bacaksiz; Kivanc Yuksel
Journal:  Indian J Orthop       Date:  2020-02-10       Impact factor: 1.251

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.